Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Pediatr Crit Care Med. 2012 Jan;13(1):e33–e38. doi: 10.1097/PCC.0b013e31820ac08f

Table 3.

Neuroprotective therapy following ICP monitor placement in patients with ALF and severe hepatic encephalopathy

# of patients (%)
Mannitol 4 (28.6)
3% hypertonic saline 10 (71.4)
Pentobarbital coma to treat ICP 8(57.1)
Dopamine to maintain CPP* 7(50)
Norepinephrine to maintain CPP* 7(50)

CPP* = cerebral perfusion pressure